GC Green Cross Anthrax Vaccine "Baeriteurakseuju" Wins Grand Prize at Korea New Drug Development Awards

Differentiated Safety Compared to Existing Vaccines

GC Green Cross announced on the 25th that it will receive the Grand Prize at the 27th Korea New Drug Development Awards for its anthrax vaccine “Baeriteurakseuju,” which was co-developed with the Korea Disease Control and Prevention Agency.

Baeriteurakseuju. Green Cross

The Korea New Drug Development Awards were established in 1999 and are hosted by the Korea Drug Research Association, with sponsorship from the Ministry of Science and ICT, the Ministry of Health and Welfare, and the Ministry of Trade, Industry and Energy.

Baeriteurakseuju received marketing approval in April last year as Korea’s 39th domestically developed new drug and the country’s third domestically developed new drug vaccine. Unlike existing methods that directly use non-pathogenic anthrax bacteria, it significantly enhances safety by producing and purifying only the protective antigen protein, the key component of anthrax toxin, through genetic recombination. According to GC Green Cross, clinical trials confirmed excellent safety and strong immunogenicity.

The company stated that, at a time when there are only a limited number of anthrax vaccine suppliers worldwide, Baeriteurakseuju represents a symbolic achievement in the localization of strategic vaccines. It added that differentiated safety has also given the product competitiveness for entry into global markets.

Lee Jaewoo, Head of Development at GC Green Cross, and Baeriteurakseuju Product Manager Kang Jieun are scheduled to receive a commendation from the Minister of Science and ICT and a commendation from the President of the Korea Health Industry Development Institute, respectively, in recognition of their contributions to the development of Baeriteurakseuju.

“It is meaningful that Baeriteurakseuju, completed through long-term collaboration between GC Green Cross and the Korea Disease Control and Prevention Agency, has been selected for the Grand Prize at the Korea New Drug Development Awards,” said Lee Jaewoo, Head of Development at GC Green Cross. “Based on the technological capabilities and safety data we have secured, we plan to pursue exports to global markets.”

Meanwhile, GC Green Cross previously received the Grand Prize at the 25th Korea New Drug Development Awards in 2024 for its plasma-derived fractionation product “Aliglo.”